Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it has received market approval from the European Commission (EC) for BAT1806, a biosimilar version of Roche Holding AG’s (OTCM: RHHBY) Actemra/RoActemra (tocilizumab). BAT1806 is indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.
Roche’s originator drug functions as an interleukin-6 receptor inhibitor, modulating the immune response. Bio-Thera’s BAT1806 was developed in accordance with biosimilar guidelines established by regulatory authorities in the United States, the European Union (EU), and China. In April 2021, Biogen Inc. (Nasdaq: BIIB) entered into an agreement with Bio-Thera to secure development and commercialization rights for BAT1806 in markets outside of Greater China.- Flcube.com
